Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$158.24 USD

158.24
2,305,872

-0.38 (-0.24%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $158.22 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

by Zacks Equity Research

Bruker delivers better-than-expected earnings and revenues in the fourth quarter of 2024.

Zacks Equity Research

WST Stock Declines in Pre-Market Despite Q4 Earnings Beat, Margins Down

by Zacks Equity Research

West Pharmaceutical's overall top line in the fourth quarter of 2024 continues to benefit from revenue growth in its Proprietary Products segment.

Zacks Equity Research

QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract

by Zacks Equity Research

Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.

Zacks Equity Research

GE HealthCare Q4 Earnings Beat Estimates, Sales Miss, Net Margin Rises

by Zacks Equity Research

GEHC's fourth-quarter results reflect strength in the Advanced Visualization Solutions and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.

Zacks Equity Research

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

by Zacks Equity Research

CVS tops earnings and revenue estimates in the fourth quarter of 2024 amid macroeconomic impacts in the Health Care Benefits arm.

Zacks Equity Research

EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash

by Zacks Equity Research

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in the fourth quarter of 2024.

Zacks Equity Research

ECL Stock Up in Pre-Market Following Q4 Earnings Beat, Margins Expand

by Zacks Equity Research

Ecolab's robust performance across the majority of its segments drives its fourth-quarter 2024 sales despite business challenges.

Zacks Equity Research

INSP Stock Declines Despite Q4 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the fourth quarter.

Indrajit Bandyopadhyay headshot

Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings?

by Indrajit Bandyopadhyay

McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Can MCK overcome its sustaining challenges with robust finances and innovation?

Zacks Equity Research

Avantor Stock Declines Despite Q4 Earnings Beat, Margins Expand

by Zacks Equity Research

Despite AVTR's stability in proprietary chemicals and specialty procurement sales, it reports an overall soft fourth-quarter performance.

Zacks Equity Research

Quest Diagnostics Stock to Gain From Innovation Amid Industry Threats

by Zacks Equity Research

Within brain health, the robust demand for AD-detect blood tests for assessing Alzheimer's disease risk drives solid growth for DGX in the fourth quarter of 2024.

Zacks Equity Research

NVST Stock Up on Q4 Earnings and Revenue Beat, Operating Margin Crashes

by Zacks Equity Research

Envista delivers better-than-expected top and bottom-line results for the fourth quarter of 2024.

Zacks Equity Research

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

by Zacks Equity Research

OMCL returns to year-over-year revenue growth in the fourth quarter of 2024.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

PBH Q3 Earnings Beat Estimates, EPS View Raised, Shares Gain 14.8%

by Zacks Equity Research

Prestige Consumer Healthcare witnesses continued international growth in the third quarter, banking on strong sales of the Hydralyte brand.

Zacks Equity Research

HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket

by Zacks Equity Research

Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion.

Zacks Equity Research

ILMN Q4 Earnings Miss Estimates, Stock Dips in Aftermarket

by Zacks Equity Research

Illumina's fourth-quarter revenues from the consumables business show robust growth.

Zacks Equity Research

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

by Zacks Equity Research

QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024.

Zacks Equity Research

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

by Zacks Equity Research

Phibro's second-quarter fiscal 2025 results reflect the strong performance of the legacy Animal Health business.

Zacks Equity Research

ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket

by Zacks Equity Research

Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments.

Zacks Equity Research

BD Stock Falls in Pre-Market Despite Q1 Earnings Beat, Gross Margin Up

by Zacks Equity Research

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

Zacks Equity Research

ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up

by Zacks Equity Research

Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.

Zacks Equity Research

ALGN Q4 Earnings Top Estimates, Revenues Miss, Stock Falls

by Zacks Equity Research

Align Technology reports fourth-quarter 2024 revenue growth. This can be mostly attributed to the robust performance of the Imaging Systems & CAD/CAM Services business segment.

Zacks Equity Research

STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket

by Zacks Equity Research

STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning.

Zacks Equity Research

CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook

by Zacks Equity Research

CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.